rx 821002 has been researched along with lassbio-579 in 1 studies
| Studies (rx 821002) | Trials (rx 821002) | Recent Studies (post-2010) (rx 821002) | Studies (lassbio-579) | Trials (lassbio-579) | Recent Studies (post-2010) (lassbio-579) |
|---|---|---|---|---|---|
| 317 | 0 | 45 | 10 | 0 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, FR; Antonio, CB; Barreiro, EJ; Figueiredo, CD; Fraga, CA; Herzfeldt, V; Moura, BC; Noël, F; Pompeu, TE; Rates, SM | 1 |
1 other study(ies) available for rx 821002 and lassbio-579
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Design; Locomotion; Male; Mice; Piperazines; Receptor, Serotonin, 5-HT2A; Schizophrenia | 2013 |